C Seretis1, H Youssef2. 1. Department of Colorectal Surgery, Good Hope Hospital, Heart of England NHS Foundation Trust, United Kingdom. 2. Department of Colorectal Surgery, Good Hope Hospital, Heart of England NHS Foundation Trust, United Kingdom. Electronic address: haney.youssef@heartofengland.nhs.uk.
Abstract
BACKGROUND: Cytoreductive Surgery (CRS) accompanied by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a promising technique in the treatment of peritoneal metastatic disease. The complexity and the potential adverse effects of the procedure can significantly affect patients' Quality of Life (QoL). Few studies have assessed the impact of CRS + HIPEC in patients' QoL using structured and validated tools. This is a systematic review of the currently available published data, investigating the QoL after performing CRS + HIPEC for tumours of varying primary origin. METHODS: We performed a systematic review of the studies indexed in PubMed database until July 2014, using as key phrase "quality of life" and "intraperitoneal chemotherapy", including studies using only validated questionnaires for assessing quality of life parameters. RESULTS: 20 studies were identified that matched the criteria set. The results of these studies, although of significant heterogeneity, clearly demonstrate that although overall QoL scores drop in the immediate postoperative period, at an average of 3 months post procedure they recover to 80%-100% or even exceed baseline values. Furthermore, between 6 and 12 months postoperatively, overall QoL is improved in survivors compared to pre-operative status. CONCLUSIONS: CRS and HIPEC is feasible as a treatment modality in selected patients with peritoneal metastatic disease and can preserve or even improve patients' overall quality of life.
BACKGROUND: Cytoreductive Surgery (CRS) accompanied by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a promising technique in the treatment of peritoneal metastatic disease. The complexity and the potential adverse effects of the procedure can significantly affect patients' Quality of Life (QoL). Few studies have assessed the impact of CRS + HIPEC in patients' QoL using structured and validated tools. This is a systematic review of the currently available published data, investigating the QoL after performing CRS + HIPEC for tumours of varying primary origin. METHODS: We performed a systematic review of the studies indexed in PubMed database until July 2014, using as key phrase "quality of life" and "intraperitoneal chemotherapy", including studies using only validated questionnaires for assessing quality of life parameters. RESULTS: 20 studies were identified that matched the criteria set. The results of these studies, although of significant heterogeneity, clearly demonstrate that although overall QoL scores drop in the immediate postoperative period, at an average of 3 months post procedure they recover to 80%-100% or even exceed baseline values. Furthermore, between 6 and 12 months postoperatively, overall QoL is improved in survivors compared to pre-operative status. CONCLUSIONS: CRS and HIPEC is feasible as a treatment modality in selected patients with peritoneal metastatic disease and can preserve or even improve patients' overall quality of life.
Authors: Katharine E Duckworth; Richard P McQuellon; Gregory B Russell; Kathleen C Perry; Chandylen Nightingale; Perry Shen; Konstantinos I Votanopoulos; Bonny Morris; Edward A Levine Journal: J Am Coll Surg Date: 2020-01-31 Impact factor: 6.113
Authors: Omeed Moaven; Konstantinos I Votanopoulos; Perry Shen; Paul Mansfield; David L Bartlett; Greg Russell; Richard McQuellon; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2019-11-12 Impact factor: 5.344
Authors: Kurinchi Gurusamy; Claire L Vale; Elena Pizzo; R Bhanot; Brian R Davidson; Tim Mould; Muntzer Mughal; Mark Saunders; Omer Aziz; Sarah O'Dwyer Journal: BMJ Open Date: 2020-05-12 Impact factor: 2.692
Authors: Maleen Leimkühler; Judith E K R Hentzen; Patrick H J Hemmer; Lukas B Been; Robert J van Ginkel; Schelto Kruijff; Barbara L van Leeuwen; Geertruida H de Bock Journal: Ann Surg Oncol Date: 2020-04-26 Impact factor: 5.344
Authors: B J L Kooijman; J E K R Hentzen; C S van der Hilst; L B Been; R J van Ginkel; P H J Hemmer; J M Klaase; S Kruijff Journal: BJS Open Date: 2020-07-11